Altruism values for treatments of rare, severe pediatric diseases have not been estimated. This study found the altruism value for a hypothetical new Duchenne muscular dystrophy treatment to be $80 ...

Insmed is set to challenge the Duchenne muscular dystrophy (DMD) treatment space with its innovative gene therapy asset, INS1201.

Benefiting from technological and conceptual groundwork and positive early data, gene therapies are advancing in the clinic ...

Capricor Therapeutics has completed its US marketing application for deramiocel, a cell therapy the US biotech hopes will ...

Wave Life Sciences shows promising data in genetic mutation treatments, with GSK collaborations and strong financial footing.

Sarepta Therapeutics’ Duchenne muscular dystrophy therapy Elevidys handily beat analysts’ expectations in the fourth quarter ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Capricor Therapeutics seeks US FDA approval for deramiocel for the treatment of Duchenne muscular dystrophy: San Diego Saturday, January 4, 2025, 15:00 Hrs [IST] Capricor Therapeu ...